Volume : 13, Issue : 03, March – 2026
Title:
EVALUATION OF ANTICANCER ACTIVITY OF SYNTHETIC HETEROCYCLIC COMPOUNDS ON MCF-7 BREAST CANCER CELL LINE
Authors :
Chavan Vaishnavi Vasant, Shubhangi Ashok Gadekar, Komal Maruti Gadade, Mr. Chavan Alpesh Ankush, Dr. Rahul Ishwara Jadhav
Abstract :
Breast cancer is one of the most common malignancies affecting women worldwide, with increasing incidence and mortality rates. Among various in vitro models, the MCF-7 breast cancer cell line is widely used for evaluating anticancer activity due to its well-characterized biological behavior. Heterocyclic compounds represent a significant class of molecules in medicinal chemistry and have shown promising anticancer potential. This review focuses on the evaluation of synthetic heterocyclic compounds against the MCF-7 cell line, highlighting their mechanisms of action, structure–activity relationships, and therapeutic potential. The review also discusses commonly used in vitro assays and future perspectives for drug development.
Cite This Article:
Please cite this article in press Rahul Ishwara Jadhav et al., Evaluation Of Anticancer Activity Of Synthetic Heterocyclic Compounds On Mcf-7 Breast Cancer Cell Line., Indo Am. J. P. Sci, 2026; 13(03).
REFERENCES:
1. Mosmann T. Rapid colorimetric assay for cellular growth. J Immunol Methods.
2. Sharma V., et al. Heterocyclic compounds in cancer therapy. Eur J Med Chem.
3. Singh H., et al. Advances in heterocyclic chemistry. Med Chem Res.
4. Baselga J. Targeted therapy in breast cancer. Oncologist.
5. Yewale C., et al. EGFR targeting strategies. Biomaterials.
6. Brown C., et al. Drug resistance in cancer. Nat Rev Cancer.
7. Kumar D., et al. Synthetic approaches in medicinal chemistry. Chem Rev.
8. Patel N., et al. Anticancer drug discovery. Bioorg Chem.
9. Verma A., et al. Apoptosis mechanisms. Cancer Lett.
10. Chen Z., et al. Advances in breast cancer therapy. Cancer Treat Rev.
11. Ghosh S., et al. Molecular docking studies. J Mol Struct.
12. Ahmad S., et al. Nanotechnology in cancer. Drug Discov Today.
13. Zhao Y., et al. Signaling pathways in cancer. Cancer Lett.
14. El-Gamal K., et al. Pyrimidine synthesis. J Heterocycl Chem.
15. Abdel-Maksoud M., et al. Anticancer heterocycles. Eur J Pharm Sci.
16. Alafeefy A., et al. Medicinal chemistry of heterocycles. Saudi Pharm J.
17. Hopkins A. Drug discovery and SAR. Nat Rev Drug Discov.
18. Normanno N., et al. EGFR signaling. Gene.
19. Wakeling A., et al. Tyrosine kinase inhibitors. Cancer Res.
20. Ciardiello F., Tortora G. EGFR in cancer therapy. N Engl J Med.